Company news

Share this article:
A US appeals court upheld a lower court ruling finding the Plavix patent valid, meaning patent protection will be maintained until November 2011. Sanofi-Aventis and Bristol-Myers Squibb are seeking damages from Canadian drug manufacturer Apotex Inc., which launched a generic version of Plavix in 2006. BMS has claimed that it lost as much as $1.75 billion in sales after Apotex's generic version of Plavix hit the market in 2006. Plavix is the world's second biggest drug and the biggest selling product for BMS and second-biggest for Sanofi, behind Lovenox. 
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.